Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Supportive Care in Cancer
Erschienen in: Supportive Care in Cancer 1/2019

17.09.2018 | Review Article

The risk factors for depression in cancer patients undergoing chemotherapy: a systematic review

verfasst von: Shuangshuang Wen, Huimin Xiao, Yanqing Yang

Erschienen in: Supportive Care in Cancer | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This systematic review aims to identify the risk factors for depression in cancer patients undergoing chemotherapy.

Methods

Eight electronic databases were searched from inception of the databases established until August 2017. References for the included studies were retrieved by manual searching. The quality of the eligible studies was appraised by two persons using the 11-item checklist of the Agency for Healthcare Research and Quality (AHRQ).

Results

Among 5988 potentially relevant articles, 43 studies were eligible, with 17 studies of high quality and 25 studies of moderate quality. A total of 65 factors were extracted, including sociodemographic characteristics (n = 20), physiological condition (n = 20), disease and treatment (n = 12), and psychosocial factors (n = 13). Only social support, anxiety, perceived stress, and self-efficacy were found to be consistently associated with depression in cancer patients. There is not enough evidence to support the link between the other 61 factors and depression in cancer patients undergoing chemotherapy.

Conclusions

This review suggests that the development of depression programs should take social support, anxiety, perceived stress, and self-efficacy into account. More original studies with rigorous design are necessary to further confirm those 61 inconclusive risk factors for depression in cancer patients receiving chemotherapy.
Literatur
1.
Bergerot CD, Mitchell HR, Ashing KT, Kim Y (2017) A prospective study of changes in anxiety, depression, and problems in living during chemotherapy treatments: effects of age and gender. Support Care Cancer 25:1897–1904CrossRefPubMed
2.
Piacentine LB, Miller JF, Haberlein S, Bloom AS (2015) Perceived cognitive changes with chemotherapy for breast cancer: a pilot study. Appl Nurs Res 29:9–11CrossRefPubMed
3.
Duc S, Rainfray M, Soubeyran P, Fonck M, Blanc JF, Ceccaldi J, Cany L, Brouste V, Mathoulinpélissier S (2016) Predictive factors of depressive symptoms of elderly patients with cancer receiving first-line chemotherapy. Psycho-Oncology 26:15–21CrossRefPubMed
4.
Mitchell AJ, Chan M, Bhatti H, Halton M, Grassi L, Johansen C, Meader N (2011) Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol 12:160–174CrossRefPubMed
5.
Saevarsdottir T, Fridriksdottir N, Gunnarsdottir S (2010) Quality of life and symptoms of anxiety and depression of patients receiving cancer chemotherapy. Cancer Nurs 33:e1–e10CrossRefPubMed
6.
Chen SJ, Chang CH, Chen KC, Liu CY (2016) Association between depressive disorders and risk of breast cancer recurrence after curative surgery. Medicine 95:e4547CrossRefPubMedPubMedCentral
7.
Schneider S, Moyer A (2009) Depression as a predictor of disease progression and mortality in cancer patients: a meta-analysis. Cancer 115:3304–3305
8.
Polikandrioti M, Evaggelou E, Zerva S, Zerdila M, Koukoularis D, Kyritsi E (2008) Evaluation of depression in patients undergoing chemotherapy. Health Sci J 2:162–172
9.
Park H, Yoon HG (2013) Menopausal symptoms, sexual function, depression, and quality of life in Korean patients with breast cancer receiving chemotherapy. Support Care Cancer 21:2499–2507CrossRefPubMed
10.
Jehn CF, Becker B, Flath B, Nogai H, Vuong L, Schmid P, Lüftner D (2015) Neurocognitive function, brain-derived neurotrophic factor (BDNF) and IL-6 levels in cancer patients with depression. J Neuroimmunol 287:88–92CrossRefPubMed
11.
Fagundes C, Jones D, Vichaya E, Lu C, Cleeland CS (2014) Socioeconomic status is associated with depressive severity among patients with advanced non-small cell lung cancer: treatment setting and minority status do not make a difference. J Thorac Oncol 9:1459–1463CrossRefPubMedPubMedCentral
12.
Yan L, Yuan C (2011) Levels of fatigue in Chinese women with breast cancer and its correlates: a cross-sectional questionnaire survey. J Am Assoc Nurse Pract 23:153–160CrossRef
13.
Akechi T, Okuyama T, Uchida M, Nakaguchi T, Sugano K, Kubota Y, Ito Y, Kizawa Y, Komatsu H (2012) Clinical indicators of depression among ambulatory cancer patients undergoing chemotherapy. Jpn J Clin Oncol 42:1175–1180CrossRefPubMed
14.
Farrell C, Brearley SG, Pilling M, Molassiotis A (2013) The impact of chemotherapy-related nausea on patients’ nutritional status, psychological distress and quality of life. Support Care Cancer 21:59–66CrossRefPubMed
15.
Haisfield-Wolfe ME, Mcguire DB, Soeken K, Geiger-Brown J, De Forge BR (2009) Prevalence and correlates of depression among patients with head and neck cancer: a systematic review of implications for research. Oncol Nurs Forum 36:107–125
16.
Brandão T, Schulz MS, Matos PM (2017) Psychological adjustment after breast cancer: a systematic review of longitudinal studies. Psycho-Oncology 26:917–926CrossRefPubMed
17.
Caruso R, Nanni MG, Riba M, Sabato S, Mitchell AJ, Croce E, Grassi L (2017) Depressive spectrum disorders in cancer: prevalence, risk factors and screening for depression: a critical review. Acta Oncol 56:146–155CrossRefPubMed
18.
19.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700CrossRefPubMedPubMedCentral
20.
Lijun F, Shujing W, Hua W (2011) Prevalence of depression and the relationship between depression and social support in chemotherapy patients. J Qilu Nurs 17:31–32
21.
22.
Faul LA, Jim HS, Minton S, Fishman M, Tanvetyanon T, Jacobsen PB (2011) Relationship of exercise to quality of life in cancer patients beginning chemotherapy. J Pain Symptom Manag 41:859–869CrossRef
23.
24.
Xu L (2014) The change of quality of life, anxiety and depression and the influencing factors of patients with lung cancer before and after chemotherapy. Dissertation,Tianjin Medical University
25.
Mielcarek P, Nowicka-Sauer K, Kozaka J (2017) Anxiety and depression in patients with advanced ovarian cancer: a prospective study. J Psychosom Obstet Gynecol 37:57–67CrossRef
26.
Pandey M, Sarita GP, Devi N, Thomas BC, Hussain BM, Krishnan R (2006) Distress, anxiety, and depression in cancer patients undergoing chemotherapy. World J Surg Oncol 4:68CrossRefPubMedPubMedCentral
27.
Quattropani MC, Lenzo V, Filastro A (2017) Predictive factors of anxiety and depression symptoms in patients with breast cancer undergoing chemotherapy. An explorative study based on metacognitions 23:67–73
28.
29.
Wen Q, Shao Z, Zhang P, Zhu T, Li D, Wang S (2017) Mental distress, quality of life and social support in recurrent ovarian cancer patients during active chemotherapy. Eur J Obstet Gynecol Reprod Biol 216:85–91CrossRefPubMed
30.
Heinze S, Egberts F, Rötzer S, Volkenandt M, Tilgen W, Linse R, Boettjer J, Vogt T, Spieth K, Eigentler T (2010) Depressive mood changes and psychiatric symptoms during 12-month low-dose interferon-[alpha] treatment in patients with malignant melanoma: results from the multicenter DeCOG trial. J Immunother 33:106–114CrossRefPubMed
31.
Chintamani GA, Khandelwal R, Tandon M, Jain S, Kumar Y, Narayan N, Bamal R, Srinivas S, Saxena S (2011) The correlation of anxiety and depression levels with response to neoadjuvant chemotherapy in patients with breast cancer. J Royal Soc Med Cardiovasc Dis 2:15
32.
33.
Mills PJ, Parker B, Dimsdale JE, Sadler GR, Ancoli-Israel S (2005) The relationship between fatigue and quality of life and inflammation during anthracycline-based chemotherapy in breast cancer. Biol Psychol 69:85–96CrossRefPubMed
34.
35.
Saini A, Berruti A, Ferini-Strambi L, Castronovo V, Rametti E, Giuliano PL, Ramassotto B, Picci RL, Negro M, Campagna S (2013) Restless legs syndrome as a cause of sleep disturbances in cancer patients receiving chemotherapy. J Pain Symptom Manag 46:56–64CrossRef
36.
Kim SH, Kim M, Lee HS (2016) Symptom clusters in Korean patients with metastatic cancer undergoing palliative chemotherapy. J Hosp Palliat Nurs 18:292–299CrossRef
37.
Choi EK, Kim IR, Chang O, Kang D, Nam SJ, Lee JE, Lee SK, Im YH, Park YH, Yang JH (2014) Impact of chemotherapy-induced alopecia distress on body image, psychosocial well-being, and depression in breast cancer patients. Psycho-Oncology 23:1103–1110CrossRefPubMed
38.
de Moor JS, de Moor CA, Basenengquist K, Kudelka A, Bevers MW, Cohen L (2006) Optimism, distress, health-related quality of life, and change in cancer antigen 125 among patients with ovarian cancer undergoing chemotherapy. Psychosom Med 68:555–562
39.
Chou HL, Chao TY, Chen TC, Chu CM, Hsieh CH, Yao CT, Janckila AJ (2016) The relationship between inflammatory biomarkers and symptom distress in lung cancer patients undergoing chemotherapy. Cancer Nurs 40:e1–e8CrossRef
40.
Bergerot CD, Clark KL, Nonino A, Waliany S, Buso MM, Loscalzo M (2015) Course of distress, anxiety, and depression in hematological cancer patients: association between gender and grade of neoplasm. Palliat Support Care 13:115–123CrossRefPubMed
41.
Dai YL, Yang CT, Chen KH, Tang ST (2016) Changes to and determinants of quality of life in patients with advanced non-small-cell lung cancer undergoing initial chemotherapy. J Nurs Res Jnr 25:203–215
42.
Decat CS, de Araujo TC, Stiles J (2011) Distress levels in patients undergoing chemotherapy in Brazil. Psycho-Oncology 20:1130–1133
43.
Meraner V, Gamper EM, Grahmann A, Giesinger JM, Wiesbauer P, Sztankay M, Zeimet AG, Sperner-Unterweger B, Holzner B (2012) Monitoring physical and psychosocial symptom trajectories in ovarian cancer patients receiving chemotherapy. BMC Cancer 12:77CrossRefPubMedPubMedCentral
44.
Jiayuan Z, Yuqiu Z, Ziwei F, Yong X, Guangchun Z (2018) Longitudinal trends in anxiety, depression, and quality of life during different intermittent periods of adjuvant breast cancer chemotherapy. Cancer Nurs 41:62–68CrossRef
45.
Hipkins J, Whitworth M, Tarrier N, Jayson G (2004) Social support, anxiety and depression after chemotherapy for ovarian cancer: a prospective study. Br J Health Psychol 9:569–581CrossRefPubMed
46.
Polat U, Arpacı A, Demir S, Erdal S, Yalcin S (2014) Evaluation of quality of life and anxiety and depression levels in patients receiving chemotherapy for colorectal cancer: impact of patient education before treatment initiation. J Gastrointest Oncol 5:270–275PubMedPubMedCentral
47.
Gruenigen VEV, Hutchins JR, Reidy AM, Gibbons HE, Daly BJ, Eldermire EM, Fusco NL (2006) Gynecologic oncology patients’ satisfaction and symptom severity during palliative chemotherapy. Health Quality Life Outcomes 4:1–6CrossRef
48.
Ostacoli L, Saini A, Zuffranieri M, Boglione A, Carletto S, Marco ID, Lombardi I, Picci RL, Berruti A, Comandone A (2014) Quality of life, anxiety and depression in soft tissue sarcomas as compared to more common tumours: an observational study. Appl Res Qual Life 9:123–131CrossRef
49.
50.
Ostacoli L, Saini A, Ferini-Strambi L, Castronovo V, Sguazzotti E, Picci RL, Toje M, Gorzegno G, Capogna S, Dongiovanni V (2010) Restless legs syndrome and its relationship with anxiety, depression, and quality of life in cancer patients undergoing chemotherapy. Qual Life Res Int J Qual Life Aspects Treat Care Rehabil 19:531–537CrossRef
51.
52.
53.
54.
Blank TO, Bellizzi KM (2008) A gerontologic perspective on cancer and aging. Cancer 112:2569–2576CrossRefPubMed
55.
Huang CQ, Wang ZR, Li YH, Xie YZ, Liu QX (2010) Education and risk for late life depression: a meta-analysis of published literature. Int J Psychiatry Med 40:109–124CrossRef
56.
Spangler DL, Simons AD, Monroe SM, Thase ME (1996) Gender differences in cognitive diathesis-stress domain match: implications for differential pathways to depression. J Abnorm Psychol 105:653–657CrossRefPubMed
57.
Skarupski KA, Tangney C, Li H, Ouyang B, Evans DA, Morris MC (2010) Longitudinal association of vitamin B-6, folate, and vitamin B-12 with depressive symptoms among older adults over time. Am J Clin Nutr 92:330–335CrossRefPubMedPubMedCentral
58.
59.
Phillips RM (2012) Nutrition and depression in the community-based oldest-old. Home Healthcare Nurse 30:462–471CrossRefPubMed
60.
Licinio-Paixao J (1989) Hyperinsulinemia; a mediator of decreased food intake and weight loss in anorexia nervosa and major depression. Med Hypotheses 28(2):125–130CrossRefPubMed
61.
Bower JE, Ganz PA, Irwin MR, Kwan L, Breen EC, Cole SW (2011) Inflammation and behavioral symptoms after breast cancer treatment: do fatigue, depression, and sleep disturbance share a common underlying mechanism. J Clin Oncol 29:3517–3522CrossRefPubMedPubMedCentral
62.
Cho HJ, Savitz J, Dantzer R, Teague TK, Drevets WC, Irwin MR (2017) Sleep disturbance and kynurenine metabolism in depression. J Psychosom Res 99:1–7CrossRefPubMedPubMedCentral
63.
Wang XS, Shi Q, Williams LA, Mao L, Cleeland CS, Komaki RR, Mobley GM, Liao Z (2010) Inflammatory cytokines are associated with the development of symptom burden in patients with NSCLC undergoing concurrent chemoradiation therapy. Brain Behav Immun 24:968–974CrossRefPubMedPubMedCentral
64.
Krebber AMH, Buffart LM, Kleijn G, Riepma IC, Bree RD, Leemans CR, Becker A, Brug J, Straten AV, Cuijpers P (2014) Prevalence of depression in cancer patients: a meta-analysis of diagnostic interviews and self-report instruments. Psycho-Oncology 23:121–130CrossRefPubMed
65.
Gariépy G, Honkaniemi H, Quesnel-Vallée A (2016) Social support and protection from depression: systematic review of current findings in Western countries. Br J Psychiatry 209:284–293CrossRefPubMed
66.
Jacobson NC, Newman MG (2014) Avoidance mediates the relationship between anxiety and depression over a decade later. J Anxiety Disord 28(5):437–445CrossRefPubMedPubMedCentral
67.
Bandura A (1977) Self-efficacy: toward a unifying theory of behavioral change. Psychol Rev 84:191–215CrossRefPubMed
Metadaten
Titel
The risk factors for depression in cancer patients undergoing chemotherapy: a systematic review
verfasst von
Shuangshuang Wen
Huimin Xiao
Yanqing Yang
Publikationsdatum
17.09.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 1/2019
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-018-4466-9

Weitere Artikel der Ausgabe 1/2019

Supportive Care in Cancer 1/2019 Zur Ausgabe

Original Article

Patient-reported treatment-related symptom burden for patients with advanced melanoma in Canada

Original Article

The impact of an expressive writing intervention on quality of life among Chinese breast cancer patients undergoing chemotherapy

Original Article

The impact of automated screening with Edmonton Symptom Assessment System (ESAS) on health-related quality of life, supportive care needs, and patient satisfaction with care in 268 ambulatory cancer patients

Review Article

Reproductive health care across the lifecourse of the female cancer patient

Original Article

The role of psychosocial resources for long-term breast, colorectal, and prostate cancer survivors: prevalence and associations with health-related quality of life

Original Article

Nausea in advanced cancer: relationships between intensity, burden, and the need for help

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise